U.S., Sept. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07158164) titled 'DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment' on Aug. 28.
Brief Summary: To prospectively evaluate the efficacy and safety of DPYD-guided dosing strategies in a real-world clinical setting, specifically by comparing the incidence of severe (Grade 3 and 4) fluoropyrimidine-related toxicities of heterozygous DPYD variant patients assigned to DPYD-guided reduced dosing versus patients with standard dosing in the control arm.
Study Start Date: Sept. 02
Study Type: INTERVENTIONAL
Condition:
Colorectal Neoplasms
Breast Neoplasms
Head and Neck Neoplasms
Gastro-Intestinal Intraepithelial Neoplasia
Intervention:
DRUG...